Tina Han, MD
Nephrology · Mt Prospect, ILNPI 1336141126
Payments from drug & device makers
Across 24 payments — averaging $25.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$149
- Nxstage Medical, Inc.$91
- Amgen$76
- Vifor Pharma, Inc.$74
- Calliditas Therapeutics US Inc.$68
- AstraZeneca$60
- plus $101 from 5 others
What the payments were for
- Food & beverage$59997%
- Education$203%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 6 | $149 |
| Nxstage Medical, Inc. | 2 | $91 |
| Amgen | 3 | $76 |
| Vifor Pharma, Inc. | 3 | $74 |
| Calliditas Therapeutics US Inc. | 3 | $68 |
| AstraZeneca(2 entities) | 2 | $60 |
| Akebia Therapeutics Inc | 1 | $21 |
| Bayer | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Novartis | 1 | $19 |
| Lilly USA, LLC | 1 | $19 |
How this compares
$619 in reported general payments places this provider in the 45th percentile of 524 nephrology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 24 | $63,945 |
| VeltassaPatiromer Calcium Sorbitex | 35 | $35,050 |
| Sevelamer Carbonate | 46 | $10,392 |
| Bumetanide | 24 | $1,549 |
| Calcium Acetate | 12 | $1,542 |
| Gentamicin Sulfate | 30 | $1,388 |
| Calcitriol | 73 | $1,265 |
| Losartan Potassium | 78 | $1,159 |
| Amlodipine Besylate | 103 | $906 |
| Hydralazine Hcl | 45 | $886 |
| Furosemide | 49 | $425 |
| Torsemide | 14 | $387 |
| Metoprolol Succinate | 22 | $376 |
| Carvedilol | 37 | $283 |
| Allopurinol | 29 | $263 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Mt Prospect
- Myles WolfChicago$22.4M
- Suneel UdaniHinsdale$6.8M
- Paul CrawfordEvergreen Park$3.1M
- Beatrice ConcepcionChicago$2.6M
- April KennedyChicago$1.8M
- Khaleel SayeedChicago$1.7M
- Woojin James ChonHines$1.1M
- Mohammed AhmedBolingbrook$1.1M
- Tamara IsakovaChicago$763K
- William WhittierChicago$668K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.